[{"id":"77a99bd4-43de-4679-bbaf-fb28aca9105d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06078930","created_at":"2023-10-12T22:13:56.559Z","updated_at":"2024-07-02T16:35:33.699Z","phase":"","brief_title":"Development of Novel Gastric Cancer Screening and Diagnosis Technologies Using Tongue Imaging and Study of Tongue Image Changes Mechanisms","source_id_and_acronym":"NCT06078930","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 100000","initiation":"Initiation: 04/06/2021","start_date":" 04/06/2021","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-10-12"},{"id":"0785c06c-1bec-445f-b1f6-0f9415e68492","acronym":"","url":"https://clinicaltrials.gov/study/NCT01268579","created_at":"2021-01-18T05:07:46.939Z","updated_at":"2024-07-02T16:35:35.116Z","phase":"","brief_title":"Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma","source_id_and_acronym":"NCT01268579","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR • CDKN1A","pipe":"","alterations":" ","tags":["EGFR • CDKN1A"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 12/28/2010","start_date":" 12/28/2010","primary_txt":" Primary completion: 10/31/2022","primary_completion_date":" 10/31/2022","study_txt":" Completion: 10/31/2022","study_completion_date":" 10/31/2022","last_update_posted":"2023-10-02"},{"id":"55fc9994-8b85-42e1-a322-c1481d787dea","acronym":"","url":"https://clinicaltrials.gov/study/NCT03602079","created_at":"2021-01-17T17:58:25.852Z","updated_at":"2024-07-02T16:35:41.099Z","phase":"Phase 1/2","brief_title":"Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene","source_id_and_acronym":"NCT03602079","lead_sponsor":"Klus Pharma Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Sertaly (trastuzumab botidotin)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 07/16/2018","start_date":" 07/16/2018","primary_txt":" Primary completion: 01/12/2022","primary_completion_date":" 01/12/2022","study_txt":" Completion: 01/12/2022","study_completion_date":" 01/12/2022","last_update_posted":"2023-08-03"},{"id":"c153810d-16f0-40f8-9439-a64b4b0d79a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01332279","created_at":"2021-01-18T05:25:50.979Z","updated_at":"2024-07-02T16:35:51.525Z","phase":"Phase 1","brief_title":"Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy","source_id_and_acronym":"NCT01332279","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" EGFR • HIF1A","pipe":" | ","alterations":" EGFR amplification • HIF1A expression • AKT1 amplification","tags":["EGFR • HIF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • HIF1A expression • AKT1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • everolimus"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 05/01/2011","primary_completion_date":" 05/01/2011","study_txt":" Completion: 05/01/2011","study_completion_date":" 05/01/2011","last_update_posted":"2023-04-04"},{"id":"f7c6f7be-a02e-4ed6-905b-7497b36204c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02295540","created_at":"2021-01-29T07:07:15.250Z","updated_at":"2024-07-02T16:36:03.333Z","phase":"","brief_title":"Hypofractionated Radiation Therapy Followed by Surgery in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity","source_id_and_acronym":"NCT02295540","lead_sponsor":"Rutgers, The State University of New Jersey","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2022-09-28"},{"id":"e92471d9-fc4e-4170-a0ba-e8d100dcff1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05456022","created_at":"2022-07-13T12:56:27.026Z","updated_at":"2024-07-02T16:36:07.358Z","phase":"Phase 2","brief_title":"Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line","source_id_and_acronym":"NCT05456022","lead_sponsor":"Cairo University","biomarkers":" BCL2 • BAX • GAPDH • ANXA5","pipe":" | ","alterations":" BCL2 expression • BAX expression","tags":["BCL2 • BAX • GAPDH • ANXA5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • BAX expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 1000000","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-07-13"},{"id":"6ca52df8-638a-4323-b022-d68d886a646a","acronym":"ERLO-XIB","url":"https://clinicaltrials.gov/study/NCT02748707","created_at":"2021-01-18T13:27:59.774Z","updated_at":"2024-07-02T16:36:11.256Z","phase":"Phase 2","brief_title":"Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study","source_id_and_acronym":"NCT02748707 - ERLO-XIB","lead_sponsor":"Tata Memorial Hospital","biomarkers":" EGFR • TP53","pipe":"","alterations":" ","tags":["EGFR • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • celecoxib oral"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 08/18/2015","start_date":" 08/18/2015","primary_txt":" Primary completion: 02/12/2018","primary_completion_date":" 02/12/2018","study_txt":" Completion: 04/01/2023","study_completion_date":" 04/01/2023","last_update_posted":"2022-04-28"},{"id":"922ea0fb-ea5e-446c-88d6-9339060eab6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01816984","created_at":"2021-01-18T08:04:06.543Z","updated_at":"2024-07-02T16:36:23.449Z","phase":"Phase 1/2","brief_title":"PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer","source_id_and_acronym":"NCT01816984","lead_sponsor":"University of Chicago","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 04/01/2018","primary_completion_date":" 04/01/2018","study_txt":" Completion: 09/01/2020","study_completion_date":" 09/01/2020","last_update_posted":"2021-10-05"},{"id":"91461f09-f8c2-4475-8c9a-281bf9820b72","acronym":"","url":"https://clinicaltrials.gov/study/NCT00293462","created_at":"2021-07-30T23:52:26.673Z","updated_at":"2024-07-02T16:36:27.215Z","phase":"Phase 3","brief_title":"GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer","source_id_and_acronym":"NCT00293462","lead_sponsor":"Marilyn Dodd","biomarkers":" CSF2","pipe":"","alterations":" ","tags":["CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 91","initiation":"Initiation: 06/07/2005","start_date":" 06/07/2005","primary_txt":" Primary completion: 12/31/2009","primary_completion_date":" 12/31/2009","study_txt":" Completion: 12/31/2009","study_completion_date":" 12/31/2009","last_update_posted":"2021-07-30"},{"id":"00adb883-c889-477d-b8e0-365b7242c8b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01254617","created_at":"2021-01-18T05:03:32.491Z","updated_at":"2024-07-02T16:36:48.662Z","phase":"Phase 1","brief_title":"Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer","source_id_and_acronym":"NCT01254617","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["EGFR • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • lenalidomide • Datalai (cetuximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 02/10/2011","start_date":" 02/10/2011","primary_txt":" Primary completion: 01/29/2014","primary_completion_date":" 01/29/2014","study_txt":" Completion: 01/29/2014","study_completion_date":" 01/29/2014","last_update_posted":"2020-03-13"},{"id":"71b94407-444d-43f8-b380-0cdda2e2e16c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01316757","created_at":"2021-01-18T05:21:39.519Z","updated_at":"2024-07-02T16:37:13.642Z","phase":"Phase 2","brief_title":"Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer","source_id_and_acronym":"NCT01316757","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • erlotinib • carboplatin • paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 02/16/2011","start_date":" 02/16/2011","primary_txt":" Primary completion: 04/07/2015","primary_completion_date":" 04/07/2015","study_txt":" Completion: 10/03/2017","study_completion_date":" 10/03/2017","last_update_posted":"2018-02-26"},{"id":"4714e60a-6e04-4fc7-9253-4f6cdae99d09","acronym":"","url":"https://clinicaltrials.gov/study/NCT00939627","created_at":"2023-01-14T15:59:08.995Z","updated_at":"2024-07-02T16:37:14.613Z","phase":"Phase 2","brief_title":"Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab","source_id_and_acronym":"NCT00939627","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TGFB1","pipe":"","alterations":" ","tags":["TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • sorafenib"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 07/01/2009","start_date":" 07/01/2009","primary_txt":" Primary completion: 01/01/2013","primary_completion_date":" 01/01/2013","study_txt":" Completion: 01/01/2014","study_completion_date":" 01/01/2014","last_update_posted":"2018-01-23"},{"id":"a025fc2a-95e7-48da-88ed-e030234e7133","acronym":"","url":"https://clinicaltrials.gov/study/NCT00407810","created_at":"2021-01-18T01:25:43.021Z","updated_at":"2024-07-02T16:37:16.952Z","phase":"Phase 2","brief_title":"Cetuximab and Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer","source_id_and_acronym":"NCT00407810","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab)"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 10/01/2006","start_date":" 10/01/2006","primary_txt":" Primary completion: 02/01/2012","primary_completion_date":" 02/01/2012","study_txt":"","study_completion_date":"","last_update_posted":"2017-10-20"},{"id":"143ab7da-bd4a-45d2-bbab-e6be05c31e74","acronym":"","url":"https://clinicaltrials.gov/study/NCT03288298","created_at":"2021-01-18T16:14:39.692Z","updated_at":"2024-07-02T16:37:17.679Z","phase":"Phase 1","brief_title":"Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line","source_id_and_acronym":"NCT03288298","lead_sponsor":"Cairo University","biomarkers":" CASP3","pipe":"","alterations":" ","tags":["CASP3"],"overall_status":"Unknown status","enrollment":" Enrollment 4","initiation":"Initiation: 11/01/2017","start_date":" 11/01/2017","primary_txt":" Primary completion: 09/01/2018","primary_completion_date":" 09/01/2018","study_txt":" Completion: 04/01/2019","study_completion_date":" 04/01/2019","last_update_posted":"2017-09-20"},{"id":"52bf81ab-7eb7-45fc-a840-5116290d7698","acronym":"","url":"https://clinicaltrials.gov/study/NCT02007200","created_at":"2021-01-18T09:09:55.609Z","updated_at":"2024-07-02T16:37:28.301Z","phase":"Phase 2","brief_title":"Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery","source_id_and_acronym":"NCT02007200","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 07/01/2009","start_date":" 07/01/2009","primary_txt":" Primary completion: 09/01/2015","primary_completion_date":" 09/01/2015","study_txt":" Completion: 09/01/2015","study_completion_date":" 09/01/2015","last_update_posted":"2016-10-24"}]